However, recent publications demonstrate safety, evidenced by protection in terms of rates of hypoglycemic events by reducing degludec insulin dosage in subjects with T1D, even with different exercise intensity and modality (indexed by lactate threshold and potentiometers) [5]. Here, INS is linked to type 1 diabetes mellitus.